GlassScriptPhysician profile
Jasmine A Prime
NPI 1083925994
$292.34
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $60.20 | 2019-2020 | |
| Novo Nordisk INC | $44.23 | 2019-2020 | |
| Amgen INC. | $33.80 | 2019-2020 | |
| Sanofi Pasteur INC. | $33.70 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.11 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.25 | 2019-2020 | |
| Pfizer INC. | $13.27 | 2019 | |
| Merck Sharp & Dohme LLC | $12.14 | 2019 | |
| Lilly USA, LLC | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Prime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.